Skip to content
Open access

Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 13 references
Medicine

Abstract

may assist pseudoprogression interpretation, while RECIST maintains superiority in standardization, regulatory acceptance, and spatial resolution. Based on these complementary characteristics, we propose a ctDNA-enhanced RECIST framework (C) , in which ctDNA serves as an adjunct across three clinical scenarios: early ef fi cacy screening, iuPD decision-making, and treatment duration optimization.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.